Huimin Zhang

Ms. Huimin Zhang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2023 in Journal of Pediatric Urology
Verified
Journal Article
Closed access
YCYiming Chen
Yiming Chen
HZHuimin Zhang
Huimin Zhang
WZWen Zhang
Wen Zhang
WNWenwen Ning
Wenwen Ning
YCYijie Chen
Yijie Chen

8 November 2021 in Reproductive Sciences
Verified
Journal Article
Open access
PDF file
YCYiming Chen
Yiming Chen
BWBin Wu
Bin Wu
YCYijie Chen
Yijie Chen
WNWenwen Ning
Wenwen Ning
HZHuimin Zhang
Huimin Zhang
To establish a risk prediction model and the clinical value of trisomy 21 using alpha-fetoprotein variants L2 (AFP-L2) combined with maternal serum biomarkers and nuchal translucency (NT) thickness in early pregnancy. A retrospective case–control study was conducted. The subjects were divided into the case group (n = 40) or the control group (n = 40). An enzyme-linked immunosorbent assay was used to measure the maternal serum AFP-L2 level in both groups. The AFP-L2 single-index or multi-index combined risk model was used to predict the efficiency of trisomy 21. The best cut-off value and area under the curve (AUC) were determined to evaluate the predictive efficacy of different risk models constructed by AFP-L2. The maternal serum AFP-L2 level in the case group was 1.59 (0.61–3.61) Multiple of medium (MoM), which was higher than 1.00 (0.39–2.12) MoM in the control group (P < 0.001). The free beta-human chorionic gonadotropin (free β-hCG) level and NT in the case group were significantly higher than those in the control group (P < 0.001). The pregnancy-associated plasma protein A (PAPP-A) level in the case group was lower than that in the control group (P < 0.001). The AUC of AFP-L2 in predicting trisomy 21 was 0.797. After considering the maternal serum AFP-L2 level, the AUC, detection rate (DR), positive predictive value (PPV), negative predictive value (NPV), falsepositive rate (FPR), false negative rate (FNR), positive likelihood ratio (+LR), and negative likelihood ratio (-LR) were significantly improved. In this study, PAPP-A + free β-hCG + NT + AFP-L2 and PAPP-A + free β-hCG + AFP-L2 increased the integrated discrimination improvement (IDI) and net classification improvement (NRI) of predicting fetuses with trisomy 21 (1.10% and 5.27%; 11.07% and 2.78%) (1.10% and 5.27%; 11.07% and 2.78%), respectively, after considering the maternal serum AFP-L2 level. The maternal serum AFP-L2 level in early pregnancy had high sensitivity and specificity, and it was a good biomarker to predict fetuses with trisomy 21.

8 January 2025 in Heliyon
Verified
Journal Article
Open access
YCYiming Chen
Yiming Chen
BWBin Wu
Bin Wu
HZHuimin Zhang
Huimin Zhang
XCXuelian Chu
Xuelian Chu
LHLingling Huang
Lingling Huang
XLXiufeng Liang
Xiufeng Liang
To analyze the incidence and influencing factors of hypertensive disorders of pregnancy (HDP) in Hangzhou, China, between 2012 and 2021. We conducted a retrospective cohort study to analyze data relating to 155,433 pregnant women in Hangzhou, China, who were divided into eight groups: gestational hypertension (GH, 4247 cases), preeclampsia (PE, 1602 cases), severe preeclampsia (SPE, 995 cases), eclampsia (9 cases), HELLP syndrome (43 cases), chronic hypertension (43 cases), chronic hypertension combined with PE or SPE (77 cases), postpartum eclampsia (5 cases), and pregnant women with normal blood pressure (148412 cases). Odds ratios (ORs) and 95 % confidence intervals (95 % CIs) were used to show the association of factors with HDP. The total incidence of HDP was 45.17 ‰ (95 % CI: 44.14‰–46.20 ‰), and the subtypes of HDP showed an increasing trend from 2012 to 2021 (all P < 0.01). Several maternal characteristics, including maternal age (ORGH = 1.158 (1.035–1.295), 1.697 (1.478–1.948), and 2.769 (2.234–3.433), ORPE = 1.526 (1.224–1.902) to 2.506 (1.796–3.497)), non-local residence (OR = 1.124 (1.018–1.241), 1.212 (1.032–1.423), and 1.222 (1.010–1.479)), in vitro fertilization (OR = 1.263 (1.028–1.551), 1.342 (1.042–1.729) and 1.692 (1.234–2.321)), graviditas ≤1 (ORGH = 1.126 (1.035–1.226)), parity 7 days (OR = 2.098 (1.921–2.291), 2.115 (1.857–2.409), and 1.553 (1.333–1.810)), and winter birth (ORGH = 1.297 (1.196–1.408), ORPE = 1.425 (1.242–1.636)), were all identified as risk factors for GH, PE, and SPE. Furthermore, HDP may increase the risk of gestational period <37 weeks, low birth weight (LBW), fetal macrosomia, and a birth length <50 cm (all P < 0.05). The incidence of HDP and its subtypes showed an overall increasing trend from 2012 to 2021. Maternal factors and pregnancy outcomes may be strongly associated with HDP.